Kajian klinikal Migrain di New York
15 kajian untuk Migrain sedang mencari peserta di lokasi di New York.
Bandar di New York
Teks kajian rasmi (Bahasa Inggeris)
Study of EVO756 in Adults With Migraine
- Clinosis - Dent Neurologic Instite, Amherst
Mengambil pesertaFasa 2
Umur 18 hingga 64 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07616128A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- True North Neurology, Port Jefferson Station
Mengambil pesertaFasa 1
Umur 6 hingga 11 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT06995729Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
- Montefiore Medical Center, The Bronx
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT05156398MMA Embolization for Refractory Chronic Migraine
- University of Buffalo Medical Center, Buffalo
- Mount Sinai, New York
- Stony Brook University Medical Center, Stony Brook
Mengambil peserta
Umur 18 hingga 65 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06735833A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache
- Maimonides Medical Center, Brooklyn
Mengambil pesertaFasa 4
Umur 18 hingga 65 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06473597Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Dent Neurosciences Research Center, Amherst
- True North Neurology, Commack
- New York Neurology Associates, New York
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Dent Neurosciences Research Center, Amherst
- True North Neurology, Commack
- Northwell Health IRB, Great Neck
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04649242A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- Dent Neurologic Institute - Amherst /ID# 270260, Amherst
Mengambil pesertaFasa 3
Umur 12 hingga 17 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06810505Responding With Evidence and Access for Childhood Headaches
- Dent Neurological Institute, Amherst
Mengambil peserta
Umur 10 hingga 17 · Semua jantina · Dikemas kini 21 Sep 2026 · NCT05889624Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Nuvance Health Institute, Kingston
- Northwell Health, Manhasset
- Mt Sinai Icahn School of Medicine, New York
Mengambil pesertaFasa 4
Umur 18 hingga 70 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06972056Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Dent Neurologic Institute - Amherst /ID# 231182, Amherst
- SUNY Upstate Medical University /ID# 239898, Syracuse
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Dent Neuro Institute, Buffalo, Amherst
- SPRI Clinical Trials, LLC, Brooklyn
- True North Neurology, Commack
- dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 hingga 75 · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07645924A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
- True North Neurology, Commack
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 12 Jun 2026 · NCT05164172Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
- Neuroscience Institute at Great Neck, Great Neck
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 22 Mei 2026 · NCT07061847RELAXaHEAD for Headache Patients (Phase III)
- NYU Langone Health, New York
Mengambil peserta
Umur 16 hingga 80 · Semua jantina · Dikemas kini 10 Okt 2025 · NCT06077838Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.